drugset / Trial / NCT07464119
A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy
Not yet recruiting
30 enrolled
Peking University First Hospital
Hangzhou Reprogenix Bioscience, Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label clinical trial designed to assess the safety and therapeutic efficacy of iPSC-derived islet cell infusion in patients with diabetes mellitus.
Timeline
- Start
- 2026-03-16
- Primary completion
- 2028-12-31
- Completion
- 2033-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iPSC-derived islet cell | Cell therapy | — | — |